WT1 and astrocytic tumor: Yet, recent clinical trials have investigated WT1 as an immunotherapeutic target and supported its prognostic value and its potential utility as a strong immunotherapeutic target in different types of astrocytic tumors in all age groups even in cases with advanced or recurrent disease (Chiba et al., 2012; Oji et al., 2016; Sakai et al., 2017; Lee et al., 2019; Tsuboi et al., 2019; Sampson et al., 2020).